The neuropeptide catestatin is an endogenous nicotinic cholinergic antagonist that acts as a pleiotropic hormone.
C hromogranin (Cg)A, the index member of the chromogranin/secretogranin protein family, is the major soluble protein of catecholamine storage vesicles of sympathetic nerve terminals and the adrenal medulla. 1, 2 CgA is a proprotein giving rise to biological active peptides like the dysglycemic hormone pancreastatin, 3 the vasodilator vasostatin, 4 and catestatin 5 (CST) (CgA 352-372 ), which inhibits catecholamine release by acting as a nicotinic cholinergic antagonist, resulting in a negative-feedback mechanism. Although plasma CgA is high in human essential (hereditary) hypertension, the plasma concentration of CST is lower in both established cases and in normotensive subjects with a family history of the disease, 6 suggesting a mechanism whereby diminished CST might increase the risk for later development of hypertension. Consistent with the human findings, high blood pressure has been reported in mice after targeted ablation of the Chga gene (Chga knockout), and such high blood pressure can be "rescued" either by replacement with CST or introduction of the human ortholog in the Chga knockout background. 7 Angiogenesis, the growth of new vessels from the preexisting vasculature, is an important process in many physiological conditions including embryonic development and wound healing. However, defects in the regula-tion of angiogenesis often result in pathological conditions such as inflammatory diseases, ischemic heart, peripheral vascular diseases, proliferative retinopathy, and solid tumors. 8 The most potent angiogenic factors are basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). Besides bFGF and VEGF, a variety of neuropeptides like substance P (SP), secretoneurin (SN), and neuropeptide (NP)Y exert effects on endothelial cells (ECs) and induce angiogenesis. 9 -11 CST shares several features with SP such as vasodilation by CST 11a and SP 12 and having comparable pI (CST, 12.16; versus SP, 11.14) . In addition, CgA was shown to be upregulated by hypoxia in neuronal cells after transient hypoxia, 13 a typical characteristic of angiogenic factors like VEGF. Based on the above similarities of CST with angiogenic peptides, we reasoned that CST would exert effects on ECs in vitro and induce angiogenesis in vivo. The present report establishes CST as a novel angiogenic cytokine with the potential of inducing therapeutic effects in animal models of ischemia.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
CST Peptide and Antiserum
Human CST and antiserum have been described previously. 14 
Endothelial Progenitor Cell Isolation
Endothelial progenitor cells (EPCs) were isolated and cultured, and EPC chemotaxis assay was performed as described. 15 
Tube Formation Assay
Tube formation assay was performed as described. 10 Some Matrigel assays were performed with a mixture of 5000 HUVECs and 3000 DiI LDL-labeled EPCs. 16 The association of EPC to capillary structures was quantified using Image J.
Cornea Neovascularization Assay
Pellets containing 500 ng of CST, scrambled CST, or VEGF were implanted in C57/BL/6J mice as described. 10 On postoperative day 7, mice received an IV injection of 500 g of BS1 lectin conjugated to FITC (Vector Laboratories). After euthanasia, enucleated eyes were fixed in 1% paraformaldehyde and corneas dissected and examined by fluorescence microscopy.
Mouse Hindlimb Ischemia Model
C57BL/6 wild-type mice were subjected to unilateral hindlimb surgery. Mice were injected with saline or 20 g of CST into thigh and calf muscles after operation and every other day for weeks 1 and 2 and 2 times per week for weeks 3 and 4. Limb necrosis status (see also the Online Data Supplement) was determined on days 7, 14, and 28.
Bone Marrow Transplantation Model
Bone marrow transplantation (BMT) was performed as described. 15, 17 Labeling of functional vessels and of EPCs in BMT mice was performed 3 weeks after induction of ischemia as described. 17 EPCs are expressed as number of double positive cells per high-power field (magnification, ϫ100).
For confocal microscopy, a Broadband Confocal Leica TCS SP5 microscope (lenses: HCX PL APO CS 20ϫ0.7 [dry] and HCX PL APO CS 63ϫ1.2 [water]) was used.
Blood Flow Measurement
Blood flow measurements were performed using a laser Doppler perfusion imaging (LDPI) analyzer (Moor Instruments). Blood perfusion is expressed as the LDPI index representing the ratio of left (operated, ischemic leg) versus right (not-operated, not-ischemic leg) limb blood flow.
Immunohistochemistry
CD31 and ␣-smooth muscle actin (SMA) staining were performed as described. 10, 18 For fluorescent microscopy, appropriate secondary antibodies (Alexa 488 for SMA and Alexa 594 for CD31; both from Invitrogen 1:200) were used.
Results

In Vitro Results
CST Effects on Migration, Proliferation, and Apoptosis in ECs In Vitro
CST caused dose-dependent induction of chemotaxis in human umbilical vein endothelial cells (HUVECs) with a maximum effect at 1 nmol/L (relative chemotaxis index [CI], 1.67Ϯ0.06, PϽ0.01 versus control; Figure 1a ) comparable to other angiogenic factors like VEGF or SN. 10 CST also induced proliferation of HUVECs (as determined by cell number) with a maximum effect at 1 nmol/L (relative cell number, 1.85Ϯ0.11; PϽ0.01 versus control), and such effect was blocked by pretreatment with CST antibody (relative cell number, 0.97Ϯ0.06; PϽ0.05 versus CST) and blockade of MAPK by PD (relative cell number, 1.19Ϯ0.09; PϽ0.05 versus CST), indicating specificity of CST effect and its signaling through MAPK pathway ( Figure 1c ). CST-induced EC proliferation was also determined by bromodeoxyuridine (BrdUrd) staining ( Figure  1d ). CST, like VEGF, significantly increased BrdUrd incorporation in ECs.
To test the potential effects of CST on EC apoptosis, HUVECs were serum-starved and stained for TUNEL and DAPI. CST caused significant inhibition of apoptosis (percentage of TUNEL-positive apoptotic cells of DAPIpositive cells: control 23.0Ϯ0.7%, CST 10.4Ϯ0.5%; PϽ0.01, control versus CST; Figure 1e ). Inhibition of CST-induced antiapoptotic effect by wortmannin (WM) indicates that PI-3 kinase/Akt pathway mediates this effect ( Figure 1e ).
Inhibition of CST-mediated effects by PD and WM indicates involvement of MAPK and PI3-kinase/Akt pathways. CST signaling was evaluated by Western blotting, which ECs were stimulated with CST at 1 nmol/L and 300 nmol/L, with VEGF (50 ng/mL) (all 10 minutes) with the combination of VEGF and CST 300 nmol/L or with 20% FBS, and extracts were analyzed for ERK or Akt activation by Western blotting. CST induced ERK and Akt phosphorylation at low and even more at high concentrations and did not block VEGF-induced stimulation of these pathways. Actin and tubulin stains were used as loading controls.
revealed activation of extracellular signal-regulated kinase (ERK) and Akt, as judged by phosphorylation of ERK and Akt (Figure 1f ). CST was able to stimulate ERK and Akt phosphorylation at 1 and 300 nmol/L; VEGF was used as positive control. In contrast to the N-terminal CgA peptide vasostatin, 19 CST did not inhibit VEGF-induced ERK activation in ECs.
CST Induction of Angiogenesis In Vitro
CST induced angiogenesis in vitro, as demonstrated by increments in capillary tube formation in a Matrigel assay ( Figure 2) , with a maximum effect at 1 nmol/L (relative capillary tube formation, 1.77Ϯ0.08; PϽ0.01 versus control) comparable to VEGF or SN. Conversely, a scrambled peptide exerted no effect. Pretreatment with CST antibody completely abolished CST-induced tube formation (tube formation, 0.87Ϯ0.1; PϽ0.01 versus CST), indicating specificity of observed effects. In addition, CST-induced tube formation was totally inhibited by coincubation of CST with PD (tube formation 0.89Ϯ0.11, PϽ0.01 versus CST), indicating CST signaling through MAPK pathway in in vitro angiogenesis.
In Vivo Results
CST Effect on Cornea Neovascularization Assay
To further establish the role of CST in angiogenesis, we took advantage of the in vivo cornea neovascularization assay. We found that scrambled CST (Figure 3 , left) did not induce growth of new vessels toward the pellet, whereas CST induced growth of arteries out of the limbus artery leading to a capillary network around the pellet. Of note, vessels reaching the limbus vein and presumably representing veins were also observed ( Figure 3 , middle). VEGF was used as positive control and showed a distinct pattern of neovascularization with higher density of capillaries at the leading front of vessels (Figure 3 , right).
CST Effects on Hindlimb Ischemia Model
Intramuscular injection of CST into the ischemic limb significantly inhibited tissue necrosis and amputation as shown by reduced necrosis score 14 and 28 days after induction of ischemia and CST treatment (necrosis score day 28: control, 1.8Ϯ0.12; CST, 1.3Ϯ0.1; PϽ0.05; Figure  4a ). Furthermore, CST improved blood perfusion, as judged by LDPI (Figure 4b ). Three and 4 weeks after induction of ischemia, LDPI ratio increased significantly in CST-treated group as compared with saline-treated group (4 weeks: saline, 0.76Ϯ0.04 versus CST, 0.94Ϯ0.03, PϽ0.01; Figure 4b ). Blood vessel density in ischemic muscle immunohistochemistry was determined by CD31 staining (detecting ECs) and by ␣-SMA (detecting pericytes/smooth muscle cells). Significantly higher densities of capillaries (CD31-positive vessels) were noticeable in CST-treated mice 4 weeks after surgery (capillaries/mm 2 : CST, 845.5Ϯ47.8; saline, 530.4Ϯ41.8; PϽ0.01; Figure 4c ). In addition, we observed increased density of ␣-SMA-positive vessels after CST treatment (␣-SMA-positive vessels/mm 2 : CST 7.5Ϯ0.5 and saline 3.9Ϯ0.7; PϽ0.01; Figure 4d ). These findings of increased density of arterioles/arteries after CST treatment are consistent with the induction of arteriogenesis by this peptide. We injected CST in green fluorescence protein (GFP) BMT mice subjected to hindlimb ischemia for 3 weeks to evaluate CST-induced vasculogenesis in vivo. CST induced incorporation of EPCs, as shown by increased number of cells double positive for BS1-lectin (injected IV staining host vessels) and for GFP (bone marrow-derived cells after transplantation). Examination of double positive cells per high-powered field (ϫ100) revealed the following: control, 9.6Ϯ2.1; CST, 21.7Ϯ2; PϽ0.001 (Figure 5a ). When we examined peripheral blood of these mice, we observed increased numbers of flk-1 ϩ /GFP ϩ cells (percentage of GFP ϩ cells) in CST-treated mice (saline:
1.2Ϯ0.25; CST: 3.1Ϯ0.4; PϽ0.05). We also used confocal microscopy to improve colocalization of DAPI-, GFP-, and rhodamine lectin-positive cells. As shown in Figure 5b (right bottom image) cells positive for DAPI, GFP, and lectin can be detected (arrowheads).
CST-Induced Effects Are Mediated by bFGF
To assess effects of VEGF or bFGF on CST-mediated in vitro angiogenesis, CST was incubated with neutralizing VEGF and bFGF antibodies. Inhibition of VEGF did not influence CST-induced tube formation, but bFGF antibody completely inhibited CST-mediated effects (tube formation CST, 2.05Ϯ0.08; CSTϩVEGF-Ab, 1.98Ϯ0.12; CSTϩbFGF-Ab, 1.3Ϯ0.06; PϽ0.05, CST versus CSTϩbFGF-Ab; Figure 6a ). Additionally, bFGF antibody inhibited CST-induced MAPK activation in ECs. When we performed a time course of CST-induced MAPK activation in HUVECs, a biphasic activation of MAPK was observed with a maximum at 10 and 50 minutes (Figure 6b ). Whereas early activation of MAPK was not influenced by bFGF antibody, late activation of MAPK was blocked by bFGF inhibition, indicating that CST-mediated late activation of MAPK is mediated by bFGF. Because bFGF mRNA was not upregulated by CST over a broad range of concentrations and time points (data not shown and Online Data Supplement), we evaluated whether CST releases bFGF protein from ECs. We found that ECs stimulated by 1 nmol/L CST released bFGF into cell supernatant from 30 minutes to 6 hours, with a maximum at 1 hour (pg/mL: control, 28.6Ϯ2.2; CST, 53.8Ϯ3.4; PϽ0.01; Figure   6c ). Concentration of bFGF was not changed in heparin wash solutions or cell lysates after CST treatment (data not shown). To evaluate whether CST stimulates bFGF signaling, we performed studies on FGF receptor (FGFR)1 activation. We observed that CST (after 60 minutes), like bFGF (after 30 minutes), stimulated phosphorylation of FGFR1 (Figure 6d ). To investigate the mechanism of bFGF release, cells were incubated with substances inhibiting different signaling transduction pathway. We observed that inhibition of MAPK by PD blocked CST-induced bFGF release, whereas inhibition of PI3-kinase (by WM), of protein kinase C (by GFX), or of Rho kinase (by Y26732) had no effect (Figure 6e ). We also found that PD and FGF antibody inhibited CST-induced FGFR1 activation indicating that CST transactivates FGF receptor by release of bFGF (Figure 6f) .
In vivo, inhibition of bFGF by a neutralizing antibody inhibited CST-induced effects on angiogenesis, as shown by increased necrosis score (Figure 6g ) and impaired blood perfusion in LDPI measurements (day 28: CSTϩIgG, 0.75Ϯ0.3; CSTϩbFGF-Ab, 0.46Ϯ0.04; nϭ7; PϽ0.01; Figure 6h ; control day 28: 0.55Ϯ0.08; PϽ0.05 versus CSTϩIgG, nϭ3, data not shown). Additionally, CSTinduced vasculogenesis in the GFP BMT mouse was inhibited by blockade of bFGF, as demonstrated by reduced GFP ϩ /lectin ϩ EPCs in ischemic limbs (EPCs per high-powered field: control, 8.8Ϯ0.8; CSTϩIgG, 15.9Ϯ1.2; CSTϩbFGFAb, 10.8Ϯ0.8; PϽ0.05, CSTϩIgG versus CSTϩbFGF-Ab; Figure 6i ) and reduced circulating flk-1 ϩ /GFP ϩ cells (percentage of GFP ϩ cells; control, 1.2Ϯ0.25; CSTϩIgG, 3.1Ϯ0.4; CSTϩbFGF Ab, 1.5Ϯ0.3; PϽ0.05, CSTϩIgG versus CSTϩbFGF-Ab; Figure 6j ).
Discussion
Overview CST was initially described as a potent endogenous nicotinic cholinergic antagonist inhibiting nicotine-evoked catecholamine secretion from PC12 cells and primary cultures of bovine chromaffin cells. Subsequently, CST was established as a pleiotropic peptide. CST acts as a negative regulator of hypertension, 7 inotropy, and lusitropy. 20 CST induces histamine release in vivo in rat 21 and in vitro from mast cells. 22 Furthermore, CST induces directed migration of human blood monocytes, 14 which qualifies CST to be an inflammatory cytokine. 14 Recently , CST has been shown to induce vasodilation in human dorsal hand vein 11a The present findings establish CST as an angiogenic peptide.
CST Induces Effects in ECs
Inflammation and hypoxia are usually accompanied or followed by increased generation of blood vessels. 8 CgA, the precursor of CST, has been shown to be upregulated in brain in response to hypoxia, 13 as has been reported previously for angiogenic factors like VEGF. Here, we found that CST exerts several effects on ECs including EC migration and proliferation, and consistent with previous findings in wellestablished angiogenic peptides VEGF and bFGF, 23 CST also signals through MAPK pathway to induce these effects. Furthermore, inhibition of CST-induced chemotaxis of ECs by PTX indicates CST signaling through G proteins. PI3kinase/Akt pathway plays a pivotal role in EC survival and we show that CST stimulates Akt phosphorylation, that CST inhibits EC apoptosis, and that inhibition of PI3-kinase by WM abrogates CST-mediated effect. These data suggest that CST signals through the PI3-kinase/Akt pathway to inhibit HUVEC apoptosis.
CST Effects on Other Vascular Cells (EPCs, SMCs), Vasculogenesis, and Arteriogenesis
Besides its effects on ECs, CST also induced chemotaxis on other vascular cells like EPCs or SMCs (see the Online Data Supplement). CST also exerted incorporation of EPCs into vascular structures in vitro, and inhibition of bFGF blocked this effect, indicating that bFGF, a factor reported to attract EPCs, 24 mediates CST-induced effects (see below). These findings indicate that this peptide may also induce postnatal vasculogenesis. Consistent with this, we found that CST increases incorporation of EPCs in ischemic hindlimbs in GFP BMT mice, which is a wellcharacterized model to study these cells, 16, 17 findings that were also confirmed by confocal microscopy. We also found increased numbers of arteries/arterioles in CST treated ischemic hindlimbs, consistent with induction of arteriogenesis. Upregulation of PDGF-B in ECs might indicate that CST induces maturation of capillaries. 25 In contrast, MCP-1, an important regulator of maturation of preexisting collaterals, was not increased by CST. 26 
CST Effects on Angiogenesis In Vivo
Consistent with angiogenic peptides, CST induces angiogenesis in vivo in the mouse cornea neovascularization assay. This in vivo finding further strengthened the ability of CST to induce angiogenesis in the hindlimb ischemia model. Serial measurements of blood perfusion point out that CST increases perfusion to levels before ligation of the femoral artery, yielding a significant better value compared with saline-injected animals. These observations establish CST as a novel angiogenic cytokine. In this context, it is also interesting that the CST precursor CgA was found in motor nerve endplates of skeletal muscles. 27 Future studies will have to reveal whether CST plays a role in physiological processes like nerve-muscle signal transmission or in the pathophysiology of injured skeletal muscle cells, in addition to its ability to increase blood perfusion to these cells.
CST Effects Are Mediated by bFGF
Indirect angiogenic factors like sonic hedgehog induce their effects by upregulation of other, direct angiogenic cytokines like VEGF. 28 Furthermore, effects of factors like PDGF-BB or prostaglandin E on vascular cells or angiogenesis have been shown to be mediated by bFGF. 29, 30 We therefore tested whether CST-mediated effects on ECs depend on VEGF or bFGF and found that inhibition of bFGF by a neutralizing antibody indeed blocked CSTmediated in vitro angiogenesis and late MAPK activation. Additionally, we found that CST releases bFGF from ECs with a maximum as early as 1 hour and stimulates FGFR1 activation. Release of bFGF was blocked by inhibition of MAPK, indicating that this signaling pathway is necessary for CST-induced bFGF release. Furthermore, inhibition of bFGF and MAPK blocked CST-induced FGFR1 activation. This finding, as well as the observation that CSTinduced FGFR1 activation was delayed compared with bFGF, indicates that CST transactivates FGFR1 by release of bFGF. Therefore, we propose a model for CST action in which bFGF is released from ECs by CST via a MAPKdependent mechanism, stimulates FGFR1, leading to a second, late activation of MAPK after 50 minutes, in addition to a first, direct CST-mediated MAPK activation independent of bFGF after 10 minutes. This prolonged MAPK stimulation seems to be necessary for CSTmediated EC function, as shown by blockade of CSTinduced capillary tube formation by inhibition of bFGF. A similar effect of bFGF on PDGF-BB-induced vascular SMC function has been reported previously. 29 Additionally, we also were able to demonstrate that CST-induced effects in vivo depend on bFGF, as shown by increased necrosis, decreased blood perfusion, reduced EPCs in ischemic muscles, and reduced flk-1/GFP ϩ cells in the circulation in mice treated with a neutralizing bFGF-Ab. These findings might indicate that bFGF mediates CSTinduced mobilization and homing to ischemic muscle tissue.
It should be pointed out that the N-terminal CgA peptide vasostatin inhibits VEGF-induced angiogenesis. In fact, vasostatin blocked VEGF-induced MAPK activation in ECs and inhibited angiogenesis exerted by this factor in vivo in the Matrigel assay. 19 These findings indicate selective inhibition of EC function and angiogenesis by the CgA peptides. Future studies will determine why 2 peptides (vasostatin and CST) derived from CgA exert opposite effects on angiogenesis. It is yet to be determined whether CgA exhibits differential processing to vasostatin and CST in response to different physiological demands. In this context, it is also interesting that TNF-␣ exhibits dose-dependent, opposing actions on angiogenesis. 31 Of note, SN, a peptide derived from another member of the chromogranin/secretogranin family, secretogranin II, also induces therapeutic angiogenesis. 16 Several angiogenic cytokines have been used to treat patients experiencing peripheral arterial or coronary heart disease 32 and CST, as well as SN, is emerging as a promising novel candidate in the therapy of these diseases. 
Novelty and Significance
What Is Known?
• Neuropeptides such as substance P, neuropeptide Y, or secretoneurin induce angiogenesis. • Catestatin (human chromogranin A 352-372 ; bovine chromogranin A 344 -364 ) was initially identified as a catecholamine release-inhibitory peptide inhibiting catecholamine secretion in an autocrine/paracrine manner by acting as a nicotinic cholinergic antagonist. • Subsequent studies established catestatin as a pleiotropic peptide that lowers blood pressure. It induces vasodilation, is a negative inotrope, and has antimicrobial activity. It also stimulates monocyte chemotaxis.
What New Information Does This Article Contribute?
• Catestatin induces migration and proliferation of endothelial cells (ECs) and stimulates chemotaxis in vascular smooth muscle cells or endothelial progenitor cells in vitro. These effects are mediated by the activation of Akt and mitogen-activated protein kinase (MAPK) in ECs. • Catestatin acts as an angiogenic factor in vivo, specifically in the cornea neovascularization model and the hindlimb ischemia model. It stimulates the incorporation of endothelial progenitor cells into ischemia hindlimbs. • Both the in vitro and in vivo effects of catestatin were blocked by a neutralizing basic fibroblast growth factor (bFGF) antibody, impli-cating the induction of bFGF-mediated signaling by catestatin via stimulation of bFGF release from ECs and activation of FGF receptor-1.
We hypothesized that the neuropeptide catestatin induces the formation of new blood vessels because of its reported effects on vasodilation coupled with hypoxia-induced upregulation of the catestatin precursor chromogranin A. We found that catestatin induces chemotactic, proliferative, and antiapoptotic effects on ECs in vitro by activating Akt and MAPK. Catestatin induced angiogenesis in the mouse cornea neovascularization assay. In the hindlimb ischemia model, catestatin therapy improved blood flow and reduced necrosis. Immunofluorescent studies revealed increased density of capillaries and arteries and incorporation of endothelial progenitor cells by catestatin, implying that the peptide induces angiogenesis, arteriogenesis, and postnatal vasculogenesis. The in vitro and in vivo effects of catestatin were inhibited by a neutralizing bFGF antibody, indicating that bFGF mediates the action of catestatin. Of note, catestatin releases bFGF from ECs and stimulates FGF receptor-1 in these cells. These findings indicate that catestatin induces therapeutic angiogenesis in the hindlimb ischemia model. Additional studies are required to evaluate the therapeutic potential of this peptide in other ischemic conditions such as ischemic heart disease.
